Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy with Lumen-Apposing Metal Stent for Gastric Outlet Obstruction from Malignant Unresectable Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 9, 2025
Alzheimer's Network for Treatment and Diagnostics (ALZ-NET)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BENFO-TEAM)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
Phase II Study of Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tum
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025